Bioxodes is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of therapeutics for patients with thrombo-inflammatory diseases. We leverage our deep understanding of the thrombotic and inflammatory processes to design novel product candidates with an aim to address unmet medical needs.
Location: Belgium
Employees: 1-10
Total raised: $25.9M
Founded date: 2013
Investors 1
Funding Rounds 4
| Date | Series | Amount | Investors |
| 16.12.2025 | - | $6.43M | Newton Bio... |
| 12.02.2025 | - | $2.8M | - |
| 21.11.2023 | Series A | $13.14M | - |
| 26.11.2013 | Seed | $3.53M | - |
Mentions in press and media 8
| Date | Title | Description |
| 16.12.2025 | Bioxodes: €5.5 Million Series A Extension Raised To Advance BIOX-101 Toward Pivotal Hemorrhagic Stroke Trial | Bioxodes SA, a clinical-stage biopharmaceutical company developing therapies for thrombotic and inflammatory diseases, has raised a €5.5 million Series A extension to continue preparations for a potentially registrational Phase 2b trial of ... |
| 10.12.2025 | Righteous Felon Receives Investment from GroundForce Capital | Righteous Felon, a San Francisco, CA-based company which specializes in meat-snack category, received an investment from GroundForce Capital. The amount of the deal was not disclosed. The company intends to use the funds to expand its natio... |
| 12.02.2025 | Bioxodes Raises €2.7M in Funding | Bioxodes, a Gosselies, Belgium-based clinical stage biopharmaceutical company, raised €2.7M in Series A extension funding. Backers were not disclosed. Led by CEO Marc Dechamps, Bioxodes is a clinical stage biopharmaceutical company developi... |
| 21.11.2023 | Bioxodes Raises €12M in Series A Funding Round | Bioxodes, a Gosselies, Belgium-based biopharmaceutical company which specializes in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, raised €12M in Series A funding. This financial... |
| 19.09.2023 | Can Novel Biotech Therapeutics Revolutionize Global Health Care Practices? | Key Takeaways: Bioxodes is a startup company in the biotechnology and health care industry, working on advanced therapeutics using natural sources. The company’s lead program, Ir-CPI, is a groundbreaking antithrombotic for the prevention of... |
| 26.11.2013 | Bioxodes Raises EUR 2.6M in Seed Funding | MARCHE-EN-FAMENNE, BELGIUM, Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million (USD 3.5 million) first seed funding round. >> Click here for more funding data on Bioxodes >&... |
| 26.11.2013 | Bioxodes Completes €2.6M Seed Funding | Bioxodes SA, a Marche-en-Famenne, Belgium-based developer of products derived from natural sources, completed a €2.6m (US$3.5m) in first seed funding round. Backers included a consortium of business angels and Belgian investment funds while... |
| - | Bioxodes | “Bioxodes is developing a novel drug candidate, Ir-CPI, for hemorrhagic stroke patients.” |